Bristol-Myers, Roche will top burgeoning I-O market worth $29B: analyst

28th January 2019 Uncategorised 0

Bristol-Myers Squibb may be falling behind in the metastatic cancer race, and Roche is dealing with biosimilar attacks on its top-selling drugs. But the two companies are the front-runners in the arguably bigger market of adjuvant immuno-oncology, according to one financial services house.

More: Bristol-Myers, Roche will top burgeoning I-O market worth B: analyst
Source: fierce